Concepedia

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths, Karen Yee, Amer M. Zeidan, Aref Al‐Kali, H. Joachim Deeg, Prapti A. Patel, Mitchell Sabloff, Mary‐Margaret Keating,

The Lancet Haematology · 2023 · 85 citations · 22 references

DOI

Concepts

References

22

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg, Heinz Tuechler, Julie Schanz et al. · Blood · 2012 · 3.1K citations · Full text

, , +12

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

, , +9

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson et al. · Journal of Clinical Oncology · 2002 · 1.8K citations

, , +16

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson · Blood · 2006 · 1.6K citations

, , +9

Decitabine improves patient outcomes in myelodysplastic syndromes

Hagop M. Kantarjian, Jean‐Pierre J. Issa, C Rosenfeld et al. · Cancer · 2006 · 1.5K citations

, , +14